NexImmune, Inc. (NASDAQ:NEXI – Get Rating) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 538,500 shares, a growth of 13.2% from the August 15th total of 475,800 shares. Currently, 3.6% of the company's stock are sold short. Based on an average trading volume of 1,620,000 shares, the days-to-cover ratio is presently 0.3 days.

NexImmune Stock Down 16.3 %

Shares of NASDAQ NEXI opened at $0.66 on Friday. NexImmune has a 52 week low of $0.66 and a 52 week high of $18.78. The business's 50 day moving average price is $1.23 and its 200 day moving average price is $2.02. The firm has a market cap of $15.88 million, a P/E ratio of -0.25 and a beta of 1.08.

NexImmune (NASDAQ:NEXI – Get Rating) last released its quarterly earnings data on Monday, August 15th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.03). As a group, research analysts expect that NexImmune will post -2.59 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Institutional Investors Weigh In On NexImmune

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kettle Hill Capital Management LLC purchased a new stake in shares of NexImmune in the second quarter worth about $439,000. State Street Corp boosted its position in NexImmune by 9.6% in the 1st quarter. State Street Corp now owns 214,018 shares of the company's stock worth $901,000 after purchasing an additional 18,730 shares in the last quarter. EPIQ Capital Group LLC acquired a new stake in shares of NexImmune during the 1st quarter worth approximately $802,000. Millennium Management LLC purchased a new position in shares of NexImmune during the 2nd quarter valued at approximately $292,000. Finally, Brown Brothers Harriman & Co. purchased a new position in shares of NexImmune during the 1st quarter valued at approximately $517,000. 34.45% of the stock is owned by institutional investors and hedge funds.

About NexImmune

(Get Rating)

NexImmune, Inc, a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.

Featured Stories

• Get a free copy of the StockNews.com research report on NexImmune (NEXI)
• 3 Banks Worth Considering For Q4
• Stock Market: 3 Islands Of Strength In A Sea Of Red
• Is There a Cure for What is Ailing Teladoc Stock?
• MarketBeat: Week in Review 9/12 – 9/16
• No One Told These 3 Stocks It's a Down Week

Receive News & Ratings for NexImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexImmune and related companies with MarketBeat.com's FREE daily email newsletter.